Infliximab for Crohn's Disease Patients with Perianal Fistulas: Better Image, Better Life

Liwen Hong1, Chen Zhang1, Rong Fan1

  • 1Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (mainland).

Insights

Crohn's disease patients with active perianal fistulas suffer from poor quality of life and negative body image. Infliximab treatment significantly improves these psychological-social factors in patients with fistulas.

Area of Science:

  • Gastroenterology
  • Psychology

Background:

  • Crohn's disease (CD) significantly impacts patients' physical health, quality of life, and body image.
  • Active perianal fistulas in CD patients exacerbate these negative psychological and social factors.

Purpose of the Study:

  • To compare psychological-social status between CD patients with and without active perianal fistulas.
  • To determine the relationship between perianal fistula improvement and quality of life, body image, and self-esteem.
  • To assess the effect of infliximab on psychological-social status in CD patients with active perianal fistulas.

Main Methods:

  • Retrospective analysis of 301 CD patients.
  • Propensity score matching to compare groups with and without active perianal fistulas.
  • Assessment of quality of life, body image, and self-esteem.

Main Results:

  • CD patients with active perianal fistulas exhibited lower self-esteem and greater body image dissatisfaction (P<0.01).
  • Perianal fistula response correlated with improved quality of life, body image, and self-esteem (P<0.01).
  • Infliximab treatment in patients with perianal fistulas showed a 68.3% response rate, significantly higher than untreated patients (P=0.005), with greater improvements in quality of life, body image, and self-esteem (P<0.05).

Conclusions:

  • Active perianal fistulas in Crohn's disease are linked to significant body image dissatisfaction, low self-esteem, and poor quality of life.
  • Infliximab therapy offers a potential treatment to enhance the psychological-social well-being of these patients.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
349
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
359
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
324
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
336
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
342
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
338